In Vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 9, 2011, Pages 4012-4018

  Mishra, Nagendra N ^a   McKinnell, James ^a   Yeaman, Michael R ^a,b   Rubio, Aileen ^c   Nast, Cynthia C ^b,d   Chen, Liang ^e   Kreiswirth, Barry N ^e   Bayer, Arnold S ^a,b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CUBIST PHARMACEUTICALS INC   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMICROBIAL CATIONIC PEPTIDE; CELL PROTEIN; DAPTOMYCIN; NEUTROPHIL PEPTIDE 1; THROMBIN; THROMBIN INDUCED PLATELET MICROBICIDAL PROTEIN; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; CELL MEMBRANE; CELL MEMBRANE FLUIDITY; CELL WALL; CELL WALL THICKNESS; CELLULAR PARAMETERS; CROSS RESISTANCE; DRUG MECHANISM; DRUG STRUCTURE; GENE LOCUS; GENE MUTATION; HYPOTHESIS; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

ALPHA-DEFENSINS; ANTIMICROBIAL CATIONIC PEPTIDES; BETA-THROMBOGLOBULIN; DAPTOMYCIN; GENOTYPE; GENTAMICINS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; OXACILLIN; POLYMYXIN B; VANCOMYCIN;

EID: 80051824106     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00223-11     Document Type: Article

References (46)

1. Bayer, A S, et al. 1997. Hyperproduction of alpha-toxin by Staphylococcus aureus results in paradoxically reduced virulence in experimental endocarditis: A host defense role for platelet microbicidal proteins. Infect. Immun. 65:4652-4660. (Pubitemid 27463238)
2. Bayer, A S, et al. 2000. In vitro resistance of Staphylococcus aureus to thrombin-induced microbicidal protein is associated with alterations in membrane fluidity. Infect. Immun. 68:3548-3553. (Pubitemid 30340456)
3. Bertsche, U., et al. 23 May 2011. Correlation of daptomycin-resistance in a clinical Staphylococcus aureus strain with increased cell wall teichoic acid production and D-alanylation. Antimicrob. Agents Chemother. [Epub ahead of print.]
4. Boyle-Vavra, S., et al. 2011. Comparative genome sequencing of an isogenic pair of USA800 clinical methicillin-resistant Staphylococcus aureus isolates obtained before and after daptomycin treatment failure. Antimicrob. Agents Chemother. 55:2018-2025.
5. Camargo, I L, H-M Neoh, L. Cui, and K. Hiramatsu. 2008. Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype. Antimicrob. Agents Chemother. 52:4289-4299.
6. Chen, L., et al. 2009. Multiplex real-time PCR for rapid staphylococcal cassette chromosome mec typing. J. Clin. Microbiol. 47:3692-3706.
7. Collins, L V, et al. 2002. Staphylococcus aureus strains lacking D-alanine modifications of teichoic acids are highly susceptible to human neutrophil killing and are virulence attenuated in mice. J. Infect. Dis. 186:214-219. (Pubitemid 34765509)
8. Cui, L., E. Tominaga, H M Neoh, and K. Hiramatsu. 2006. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50:1079-1082. (Pubitemid 43327815)
9. Dhawan, V K, A S Bayer, and M R Yeaman. 1998. In vitro resistance to thrombin-induced platelet microbicidal protein is associated with enhanced progression and hematogenous dissemination in experimental Staphylococcus aureus infective endocarditis. Infect. Immun. 66:3476-3479. (Pubitemid 28303159)
10. Ernst, C M, et al. 2009. The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion. PLoS Pathog. 5:e1000660.
11. Fischer, A., et al. Daptomycin resistance mechanisms in clinically derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomic approach. J. Antimicrob. Chemother., in press.
12. Friedman, L., J D Adler, and J A Silverman. 2006. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob. Agents Chemother. 50:2137-2145. (Pubitemid 43807536)
13. Jones, T., et al. 2008. Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob. Agents Chemother. 52:269-278.
14. Julian, K., et al. 2007. Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis. Antimicrob. Agents Chemother. 51:3445-3448. (Pubitemid 350067576)
15. Kaatz, G W, T S Lundstrom, and S M Seo. 2006. Mechanisms of daptomycin resistance in Staphylococcus aureus. Int. J. Antimicrob. Agents 28:280-287. (Pubitemid 44402994)
16. Kilelee, E., A. Pokorny, M R Yeaman, and A S Bayer. 2010. Lysyl-phosphatidylglycerol attenuates membrane perturbation rather than surface association of the cationic antimicrobial peptide 6W-RP-1 in a model membrane system: Implications for daptomycin resistance. Antimicrob. Agents Chemother. 54:4476-4479.
17. Koo, S-P, M R Yeaman, C C Nast, and A S Bayer. 1997. The cytoplasmic membrane is a primary target for the staphylocidal action of thrombininduced platelet microbicidal protein. Infect. Immun. 65:4795-4800. (Pubitemid 27463259)
18. Kupferwasser, L I, M R Yeaman, S M Shapiro, C C Nast, and A S Bayer. 2002. In vitro susceptibility to thrombin-induced platelet microbicidal protein is associated with reduced disease progression and complication rates in experimental Staphylococcus aureus endocarditis: Microbiological, histopathologic, and echocardiographic analyses. Circulation 105:746-752. (Pubitemid 34157380)
19. Li, M., et al. 2009. Staphylococcus aureus mutant screen reveals interaction of the human antimicrobial peptide dermcidin with membrane phospholipids. Antimicrob. Agents Chemother. 53:4200-4210.
20. Lina, G., et al. 2003. Bacterial competition for human nasal cavity colonization: Role of staphylococcal agr alleles. Appl. Environ. Microbiol. 69:18-23. (Pubitemid 36077452)
21. Mishra, N N, et al. 2009. Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53:2312-2318.
22. Mishra, N N, et al. 2011. Carotenoid related alteration of cell membrane fluidity impacts Staphylococcus aureus susceptibility to host defense peptides. Antimicrob. Agents Chemother. 55:526-531.
23. Mukhopadhyay, K., et al. 2007. Reduced in vitro susceptibility of Staphylococcus aureus to thrombin-induced platelet microbicidal protein-1 (tPMP-1) is associated with alterations in cell membrane phospholipid composition and asymmetry. Microbiology 153:1187-1197. (Pubitemid 46605817)
24. Mwangi, M M, et al. 2007. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc. Natl. Acad. Sci. U. S. A. 104:9451-9456. (Pubitemid 47185800)
25. Peschel, A., et al. 1999. Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins and other antimicrobial peptides. J. Biol. Chem. 274:8405-8410. (Pubitemid 29164628)
26. Peschel, A., C. Vuong, M. Otto, and F. Götz. 2000. The D-alanine residues of Staphylococcus aureus teichoic acids alter the susceptibility to vancomycin and the activity of autolysins. Antimicrob. Agents Chemother. 44:2845-2847.
27. Pillai, S K, et al. 2007. Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF. Antimicrob. Agents Chemother. 51:2223-2225. (Pubitemid 46903123)
28. Sakoulas, G., G M Eliopoulos, J. Alder, and C T Eliopoulos. 2003. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 47:1714-1718. (Pubitemid 36548559)
29. Schriever, C A, C. Fernandez, K A Rodvold, and L H Danziger. 2005. Daptomycin: A novel cyclic lipopeptide antimicrobial. Am. J. Health Syst. Pharm. 62:1145-1158. (Pubitemid 40741054)
30. Shopsin, B., et al. 1999. Evaluation of protein A gene polymorphic region DNA sequencing for typing of Staphylococcus aureus strains. J. Clin. Microbiol. 37:3556-3563. (Pubitemid 29491091)
31. Sieradzki, K T Leski, J Dick, L Borio, and A Tomasz 2003. Evolution of a vancomycin-intermediate Staphylococcus aureus strain in vivo: Multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin-resistant S. aureus under the impact of antibiotics administered for chemotherapy. J. Clin. Microbiol. 41:1687-1693.
32. Sieradzki, K, and A. Tomasz. 1997. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J. Bacteriol. 179:2557-2566. (Pubitemid 27164554)
33. Skiest, D J 2006. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J. Clin. Microbiol. 44:655-656. (Pubitemid 43222276)
34. Steenbergen, J N, J. Alder, G M Thorne, and F P Tally. 2005. Daptomycin: A lipopeptide antibiotic for the treatment of serious Gram-positive infections. J. Antimicrob. Chemother. 55:283-288. (Pubitemid 40425449)
35. Trier, D A, et al. 2008. Platelet antistaphylococcal responses occur through P2X1 and P2Y12 receptor-induced activation and kinocidin release. Infect. Immun. 76:5706-5713.
36. Weidenmaier, C., et al. 2005. Lack of wall teichoic acids in Staphylococcus aureus leads to reduced interactions with endothelial cells and to attenuated virulence in a rabbit model of endocarditis. J. Infect. Dis. 191:1771-1777. (Pubitemid 40656767)
37. Xiong, Y Q, K. Mukhopadhyay, M R Yeaman, J. Adler-Moore, and A S Bayer. 2005. Functional interrelationships between cell membrane and cell wall in antimicrobial peptide-mediated killing of Staphylococcus aureus. Antimicrob. Agents Chemother. 49:3114-3121. (Pubitemid 41060548)
38. Xiong, Y Q, M R Yeaman, and A S Bayer. 1999. In vitro antibacterial activities of platelet microbicidal protein and neutrophil defensin against Staphylococcus aureus are influenced by antibiotics differing in mechanism of action. Antimicrob. Agents Chemother. 43:1111-1117.
39. Yang, S J, et al. 2009. Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus. J. Infect. Dis. 200:1916-1920.
40. Yang, S J, et al. 2010. Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect"). Antimicrob. Agents Chemother. 54:3161-3169.
41. Yang, S J, et al. 2010. Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: Evidence for multiple resistance mechanisms. Antimicrob. Agents Chemother. 54:3079-3085.
42. Yang, S J, et al. 2009. Regulation of mprF in daptomycin-nonsusceptible Staphylococcus aureus strains. Antimicrob. Agents Chemother. 53:2636-2637.
43. Yeaman, M R, K D Gank, A S Bayer, and E P Brass. 2002. Synthetic peptides that exert antimicrobial activities in whole blood and blood-derived matrices. Antimicrob. Agents Chemother. 46:3883-3891. (Pubitemid 35403265)
44. Yeaman, M R, Y Q Tang, A J Shen, A S Bayer, and M E Selsted. 1997. Purification and in vitro activities of rabbit platelet microbicidal proteins. Infect. Immun. 65:1023-1031. (Pubitemid 27088006)
45. Yeaman, M R 2010. Bacterial-platelet interactions: Virulence meets host defense. Future Microbiol. 3:471-506.
46. Yeaman, M R, and A S Bayer. 2000. Staphylococcus aureus, platelets, and the heart. Curr. Infect. Dis. Rep. 2:281-298.